Compare OBAI & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OBAI | LEXX |
|---|---|---|
| Founded | 2017 | 2004 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.4M | 8.7M |
| IPO Year | 2025 | 2011 |
| Metric | OBAI | LEXX |
|---|---|---|
| Price | $0.34 | $9.37 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.50 |
| AVG Volume (30 Days) | ★ 2.4M | 73.0K |
| Earning Date | 05-27-2026 | 04-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 40.53 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $9,972,000.00 | $705,923.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $601.47 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 2.42 | ★ 52.05 |
| 52 Week Low | $0.31 | $0.35 |
| 52 Week High | $19.95 | $14.37 |
| Indicator | OBAI | LEXX |
|---|---|---|
| Relative Strength Index (RSI) | 37.32 | 51.19 |
| Support Level | $0.31 | $0.62 |
| Resistance Level | $0.48 | $12.89 |
| Average True Range (ATR) | 0.04 | 1.46 |
| MACD | 0.01 | -0.27 |
| Stochastic Oscillator | 17.39 | 12.05 |
Our Bond Inc is a personal security service through its AI-powered Preventive Personal Security platform. It is trusted by corporations, cities, and universities, and has already supported many security service requests, emergencies and life-saving interventions. The cloud-based Bond Preventative Personal Security Platform provides users with remote protective services via phone app (using its Bond Preventative Personal Security Platform) and with 24/7 support from its Personal Security Agents, who are in Bond Command Centers and can respond rapidly. It offers distinct services through its phone app (the Bond App) and fully automated Bond Command Centers. Geographically, the company operates in Israel, France, and United States. It derives maximum revenue from United States.
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.